Trial NCT04922788
Publication Nguyen TP, medRxiv, 2022
Primary outcome on the report: 1) number and percentage of participants with solicited local and systemic adverse events which occurred within 7 days of vaccination and laboratory results (serum biochemistry and hematology) at days 0, 7, 28 and 42 according to FDA toxicity scoring; 2) anti-S IgG responses to Nanocovax evaluated by a chemiluminescence immunoassay (CLIA); 3) vaccine efficacy (VE) against severe illness and death; VE against symptomatic Covid-19 cases with clinical symptoms with onset at least 14 days after the second dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.